BACKGROUND AND PURPOSE: MTI has been proposed as a sensitive technique for studying microstructural brain tissue changes in patients with AD, but the course of these changes over time is largely unknown. We therefore used a placebo-controlled study of memantine to follow the evolution of tissue damage in AD by means of MTR measurements and investigated how MTR changes were related to brain atrophy and cognition. MATERIALS AND METHODS: Twenty-eight patients (76.5 ± 5.8 years) with mild to moderate AD underwent MTI, brain volume measurements, and cognitive testing at baseline and after 6 and 12 months. Nineteen healthy individuals (73.3 ± 3.2 years) served as controls. MTI was performed with a 2-minute protocol that was optimized for an enhanced MT effect and reduced motion sensitivity. Global and regional MTR measurements served as correlations with brain volumes and the MMSE score. RESULTS: AD patients had significantly lower global MTR values than controls, and showed a consistent and significant MTR reduction in all regions investigated over a period of 12 months. These MTR changes were paralleled by a brain tissue loss of 2.2% per year. Associations between MTR and cognition were found for the hippocampus, putamen, and thalamus, and were more pronounced in the left hemisphere. CONCLUSIONS: MTI in AD allows the assessment of ongoing global and regional brain damage independent of atrophy, and therefore appears to be a valuable marker for disease-related tissue changes.
BACKGROUND AND PURPOSE: MTI has been proposed as a sensitive technique for studying microstructural brain tissue changes in patients with AD, but the course of these changes over time is largely unknown. We therefore used a placebo-controlled study of memantine to follow the evolution of tissue damage in AD by means of MTR measurements and investigated how MTR changes were related to brain atrophy and cognition. MATERIALS AND METHODS: Twenty-eight patients (76.5 ± 5.8 years) with mild to moderate AD underwent MTI, brain volume measurements, and cognitive testing at baseline and after 6 and 12 months. Nineteen healthy individuals (73.3 ± 3.2 years) served as controls. MTI was performed with a 2-minute protocol that was optimized for an enhanced MT effect and reduced motion sensitivity. Global and regional MTR measurements served as correlations with brain volumes and the MMSE score. RESULTS:ADpatients had significantly lower global MTR values than controls, and showed a consistent and significant MTR reduction in all regions investigated over a period of 12 months. These MTR changes were paralleled by a brain tissue loss of 2.2% per year. Associations between MTR and cognition were found for the hippocampus, putamen, and thalamus, and were more pronounced in the left hemisphere. CONCLUSIONS: MTI in AD allows the assessment of ongoing global and regional brain damage independent of atrophy, and therefore appears to be a valuable marker for disease-related tissue changes.
Authors: Franz Fazekas; Stefan Ropele; Christian Enzinger; Faton Gorani; Alexandra Seewann; Katja Petrovic; Reinhold Schmidt Journal: Brain Date: 2005-06-15 Impact factor: 13.501
Authors: W M Van Der Flier; D M J Van Den Heuvel; A W E Weverling-Rijnsburger; A Spilt; E L E M Bollen; R G J Westendorp; H A M Middelkoop; M A Van Buchem Journal: Neurology Date: 2002-09-24 Impact factor: 9.910
Authors: W J P Henneman; J D Sluimer; J Barnes; W M van der Flier; I C Sluimer; N C Fox; P Scheltens; H Vrenken; F Barkhof Journal: Neurology Date: 2009-03-17 Impact factor: 9.910
Authors: A C G M van Es; W M van der Flier; F Admiraal-Behloul; H Olofsen; E L E M Bollen; H A M Middelkoop; A W E Weverling-Rijnsburger; J van der Grond; R G J Westendorp; M A van Buchem Journal: AJNR Am J Neuroradiol Date: 2007-10-09 Impact factor: 3.825
Authors: Jasper D Sluimer; Wiesje M van der Flier; Giorgos B Karas; Nick C Fox; Philip Scheltens; Frederik Barkhof; Hugo Vrenken Journal: Radiology Date: 2008-06-23 Impact factor: 11.105
Authors: A Ginestroni; M Battaglini; R Della Nave; M Moretti; C Tessa; M Giannelli; P Caffarra; B Nacmias; V Bessi; S Sorbi; L Bracco; N De Stefano; M Mascalchi Journal: J Neurol Date: 2009-03-01 Impact factor: 4.849
Authors: M Mascalchi; A Ginestroni; V Bessi; N Toschi; S Padiglioni; S Ciulli; C Tessa; M Giannelli; L Bracco; S Diciotti Journal: AJNR Am J Neuroradiol Date: 2013-06-06 Impact factor: 3.825
Authors: Wenna Duan; Parshant Sehrawat; Tony D Zhou; James T Becker; Oscar L Lopez; H Michael Gach; Weiying Dai Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: R Wiest; Y Burren; M Hauf; G Schroth; J Pruessner; M Zbinden; K Cattapan-Ludewig; C Kiefer Journal: AJNR Am J Neuroradiol Date: 2012-10-11 Impact factor: 3.825
Authors: Sudhakar Tummala; Bhaswati Roy; Bumhee Park; Daniel W Kang; Mary A Woo; Ronald M Harper; Rajesh Kumar Journal: J Neurosci Res Date: 2016-06-18 Impact factor: 4.164
Authors: Benjamin S Aribisala; Natalie A Royle; Susana Muñoz Maniega; Maria C Valdés Hernández; Catherine Murray; Lars Penke; Alan Gow; John M Starr; Mark E Bastin; Ian J Deary; Joanna M Wardlaw Journal: Cortex Date: 2013-12-31 Impact factor: 4.027
Authors: Michiel Sala; Albert de Roos; Gerard J Blauw; Huub A M Middelkoop; J Wouter Jukema; Simon P Mooijaart; Mark A van Buchem; Anton J M de Craen; Jeroen van der Grond Journal: BMC Neurol Date: 2015-08-07 Impact factor: 2.474